FOS and migraine disorder: Recently, the use of transient receptor potential type V1 (TRPV1) receptor antagonists has been explored as a treatment for migraine [14,15], and increased c-Fos protein expression in the trigeminal nucleus caudalis (TNC) was confirmed in experimental animal models [16].